Xenon Pharmaceuticals
XENE
91 hedge funds and large institutions have $590M invested in Xenon Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 24 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 24
37% more capital invested
Capital invested by funds: $431M → $590M (+$159M)
12% more funds holding
Funds holding: 81 → 91 (+10)
2.11% more ownership
Funds ownership: 80.04% → 82.14% (+2.1%)
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$14.4M |
| 2 |
PA
Perceptive Advisors
New York
|
+$8.73M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.83M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.79M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$7.46M |
Top Sellers
| 1 |
CC
Commodore Capital
New York
|
-$2.81M |
| 2 |
Renaissance Technologies
New York
|
-$1.31M |
| 3 |
Millennium Management
New York
|
-$1.25M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.19M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.18M |
XENE Hedge Fund Activity: Q1 2021 in Review
91 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2021, worth a combined $590M — up 37% from $431M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new XENE positions and 4 closed out — a net gain of 10 holders — while 33 added to existing stakes and 24 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $14.4M. The largest seller was Commodore Capital, cutting an estimated $2.81M.
- 91 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2021, up from 81 in Q4 2020.
- Funds reported $590M of Xenon Pharmaceuticals stock for Q1 2021, up 37% quarter-over-quarter.
- 14 funds opened new Xenon Pharmaceuticals positions in Q1 2021 and 4 closed out, a net change of +10 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2021 was Avoro Capital Advisors, an estimated $14.4M added.
- The largest Xenon Pharmaceuticals seller in Q1 2021 was Commodore Capital, an estimated $2.81M sold.
Based on aggregated 13F filings for Q1 2021.